Handbook of Vitamin C Research

Encapsulation Devices for Vitamin C 203[8] Rados, C. (2004). GRAS: Time-Tested, and Trusted, Food Ingredients. FDA Consumermagazine, 38, 2.[9] Vandervoort, J. Ludvig, A. (2002). Biocompatibile stabilizers in the preparation ofPLGA nanoparticles:a factorial design study. International Journal of Pharmaceutics,238(1-2), 77-92.[10] Stevanović, M. Jordović, B. Nedić, Z. Miličević, D. (2007). The stabilizer influence onmorphological characteristics of poly (DL-lactide-co-glycolide) nanospheres. MaterialScience Forum, 555, 447-452.[11] Nafee, N. Taetz, S. Schneider, M, Schaefer, U. F. Lehr, C.-M. (2007) Chitosan-coatedPLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters oncomplexation and transfection of antisense oligonucleotides. Nanomedicine:Nanotechnology, Biology and Medicine, 3 (3), 173-183.[12] Kozubek, A. Gubernator, J. Przeworska, E. Stasiuk, M. (2001). Liposomal drugdelivery, a novel approach: PLARosomes, Acta Biochimica Polonica, 47 (3), 639-649.[13] Lian, T. Ho, R. J. Y. (2001). Trends and developments in liposome drug deliverysystems, Journal of Pharmaceutical Sciences, 90 (6), 667-680.[14] Medina, O.P. Zhu, Y. Kairemo, K. (2004). Targeted liposomal drug delivery in cancer,Current Pharmaceutical Design, 10 (24), 2981-2989.[15] D‘Emanuele, A. Attwood, D. Abu-Rmaileh, R. (2004). The use of a dendrimerpropranololprodrug to bypass efflux transporters and enhance oral bioavailability,Journal of Controlled Release, 95, 447-453.[16] Liu, M. Frechet, J. M. (1999). Designing dendrimers for drug delivery, PharmaceuticalSciences Technology Today, 10, 393-401.[17] Stevanović, M. Ignjatović, N. Jordović, B. Uskoković, D. (2007). Stereologicalanalysis of the poly (DL-lactide-co-glycolide) submicron sphere prepared bysolvent/non-solvent chemical methods and centrifugal processing. Journal of MaterialsScience: Materials in Medicine, 18 (7), 1339-1344.[18] Yoo, H. S. (2006). Preparation of biodegradable polymeric hollow microspheres usingO/O/W emulsion stabilized by Labrafil, Colloids and Surfaces B: Biointerfaces, 52, 47-51.[19] Sahoo, S. K. Parveen, S. Panda, J. J. (2007). The present and future of nanotechnologyin human health care. Nanomedicine, 3 (1), 20-31.[20] Sumer, B. Gao, J. (2008). Theranostic nanomedicine for cancer. Nanomedicine, 3 (2), 137-140.[21] Besenbache, F. Sutherland, D. S. Hovgaard, M. B. From nanoscience tonanotechnology: Utilising the nanoscale. Toxicology Letters, 172 (1), S34.[22] Moghimi, S. M. Hunter, A. C. Murray, J. C. (2005). Nanomedicine: current status andfuture prospects. FASEB Journal, 19, 311-330.[23] Wong, S. Y. Pelet, J. M. Putnam, D. (2007). Polymer systems for gene delivery-past,present and future, Progres in Polymer Science, 32 (8-9), 799-837.[24] Ishida, M. Sakai, H. Sugihara, S. Aoshima, S. Yokoyama, S. Abe, M. (2003).Controlled release of vitamin E from thermo-responsive polymeric physico-gel.Chemical and Pharmaceutical Bulletin, 51(11), 1348—1349.